A5041329419- Health Systems, Economic Evaluations, Quality of Life
- Hemophilia Treatment and Research
- Atrial Fibrillation Management and Outcomes
- Pharmaceutical Economics and Policy
- Venous Thromboembolism Diagnosis and Management
- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Global Health Care Issues
- Cardiac Arrhythmias and Treatments
- Cardiac pacing and defibrillation studies
- Rheumatoid Arthritis Research and Therapies
- Blood Pressure and Hypertension Studies
- Global Public Health Policies and Epidemiology
- Liver Disease and Transplantation
- Multiple Sclerosis Research Studies
- COVID-19 Clinical Research Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cancer Treatment and Pharmacology
- Cardiac, Anesthesia and Surgical Outcomes
- Antiplatelet Therapy and Cardiovascular Diseases
- Blood Coagulation and Thrombosis Mechanisms
- Chronic Disease Management Strategies
- Global Maternal and Child Health
- Pharmaceutical studies and practices
- Hepatitis B Virus Studies
Politecnico di Milano
2023-2025
MultiMedica
2019-2024
University of Milano-Bicocca
2015-2024
University of Naples Federico II
2006-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2003-2024
IRCCS Istituto Auxologico Italiano
2022-2024
Fondazione Progetto Ematologia
2006-2024
Policlinico San Matteo Fondazione
2024
Institute for Health Metrics and Evaluation
2019-2023
Johannes Gutenberg University Mainz
2023
Background— Nonadherence to antihypertensive treatment is a common problem in cardiovascular prevention and may influence prognosis. We explored predictors of adherence the association with acute events. Methods Results— Using data obtained from 400 Italian primary care physicians providing information Health Search/Thales Database, we selected 18 806 newly diagnosed hypertensive patients ≥35 years age during 2000 2001. Subjects included were treated for hypertension initially free diseases....
Multiple myeloma (MM) is a plasma cell neoplasm with substantial morbidity and mortality. A comprehensive description of the global burden MM needed to help direct health policy, resource allocation, research, patient care.To describe availability effective therapies for 21 world regions 195 countries territories from 1990 2016.We report incidence, mortality, disability-adjusted life-year (DALY) estimates Global Burden Disease 2016 study. Data sources include vital registration system,...
Background Limited data are available on the characteristics, clinical management, and outcomes of patients with atrial fibrillation at risk stroke, from a worldwide perspective. The aim this study was to describe baseline characteristics initial therapeutic management non-valvular across spectrum sites which these treated. Methods Findings Global Anticoagulant Registry in FIELD (GARFIELD) is an observational newly diagnosed fibrillation. Enrollment into Cohort 1 (of 5) took place between...
Acute meningitis has a high case-fatality rate and survivors can have severe lifelong disability. We aimed to provide comprehensive assessment of the levels trends global burden that could help guide introduction, continuation, ongoing development vaccines treatment programmes.
The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. GARFIELD-AF an ongoing, global observational study of adults newly diagnosed NVAF. Two-year 17 162 prospectively enrolled in were analysed light baseline characteristics, risk profiles stroke/systemic embolism (SE), antithrombotic therapy. mean (standard deviation) age was 69.8 (11.4) years, 43.8% women, CHA2DS2-VASc score...
<h3>Objective</h3> We studied evolving antithrombotic therapy patterns in patients with newly diagnosed non-valvular atrial fibrillation (AF) and ≥1 additional stroke risk factor between 2010 2015. <h3>Methods</h3> 39 670 were prospectively enrolled four sequential cohorts the Global Anticoagulant Registry FIELD-Atrial Fibrillation (GARFIELD-AF): cohort C1 (2010–2011), n=5500; C2 (2011–2013), n=11 662; C3 (2013–2014), 462; C4 (2014–2015), 046. Baseline characteristics initiated at diagnosis...
Patients with severe hemophilia A and factor VIII inhibitors are at increased risk for serious bleeding complications progression to end-stage joint disease. Effective strategies prevent in such patients have not yet been established.We enrolled who were older than 2 years of age, had high-titer inhibitors, used concentrates known as bypassing agents a prospective, randomized, crossover study comparing 6 months anti-inhibitor coagulant complex (AICC), infused prophylactically target dose 85...
Objective To describe patterns of persistence and related primary care costs associated with first antihypertensive treatment. Design setting Retrospective cohort study during 2000–2001, using information from 320 Italian general practitioners. Participants We studied 13 303 patients newly diagnosed hypertension, who received a single prescription within 3 months after diagnosis. Main outcome measures Persistence first-line treatment, categorized as follows: continuers: continuing the...
Aims Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend a target range of international normalised ratio (INR) 2.0–3.0 for stroke prevention in atrial fibrillation (AF). We analysed the time this therapeutic (TTR) VKA-treated patients with newly diagnosed AF ongoing, global, observational registry GARFIELD-AF. Taking TTR as measure quality patient management, we its relationship 1-year outcomes, including stroke/systemic embolism (SE), major...
Understanding how prevalence, incidence, and mortality of motor neuron diseases change over time by location is crucial for understanding the causes these disorders health-care planning. Our aim was to produce estimates disability-adjusted life-years (DALYs) 195 countries territories from 1990 2016 as part Global Burden Diseases, Injuries, Risk Factors Study (GBD) 2016.
Objectives To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based mortality, stroke and bleeding risks. Design The new was developed, using stepwise regression, all then applied lower risk patients. C-statistics were compared CHA 2 DS -VASc 30-fold cross-validation control overfitting. External validation undertaken in independent dataset, Outcome Registry Better Informed...
The recommended doses for direct oral anticoagulants (DOACs) to prevent stroke and systemic embolism (SE) in patients with atrial fibrillation (AF) are described specific regulatory authority approvals. impact of DOAC dosing, according the guidance on all-cause mortality, stroke/SE, major bleeding, was assessed at 2-year follow-up newly diagnosed AF. Of a total 34,926 enrolled (2013 2016) prospective GARFIELD-AF (Global Anticoagulant Registry FIELD-AF), 10,426 received DOAC. majority (72.9%)...
The outbreak of coronavirus disease 2019 (COVID-19) has distressed our working practice. Infectious specialists, pneumologists and intensivists were not enough to face the enormous amount patients that needed hospital care; therefore, many doctors have been recruited from other medical specialties trying take care as possible. 'call duty' such for urgent COVID-19 cases, however, diverted attention with chronic conditions, which might neglected or undervalued. In this extremely difficult...